Evaluation of Retinal Structure With High Resolution Optical Coherence Tomography (OCT)
1 other identifier
observational
700
1 country
2
Brief Summary
Comparison of different OCT instruments to assess retinal thickness, correlation to fluorescein angiography, and visual outcome after therapy with anti-VEGF therapy
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2007
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedFirst Submitted
Initial submission to the registry
November 26, 2007
CompletedFirst Posted
Study publicly available on registry
November 27, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 27, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 28, 2023
CompletedNovember 29, 2023
November 1, 2023
16.9 years
November 26, 2007
November 28, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Integrity of retinal layers
End of study
Study Arms (7)
1
Healthy volunteers
2
CSME secondary to diabetic retinopathy
3
ARMD with CNV before and after therapy
4
ARMD atrophic
5
Retinal vein occlusion
6
retinitis pigmentosa
7
vitreoretinal proliferation
Interventions
Eligibility Criteria
healthy subjects and patients with macular diseases
You may qualify if:
- Macular disease
- Healthy subjects
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sebastian Wolflead
- University of Berncollaborator
Study Sites (2)
Dep. Ophthalmology, University Hospital Bern
Bern, 3010, Switzerland
Klinik und Poliklinik für Augenheilkunde, University Bern
Bern, Switzerland
Related Publications (3)
Lincke JB, Keller S, Amaral J, Zinkernagel MS, Schuerch K. Ciliary body length revisited by anterior segment optical coherence tomography: implications for safe access to the pars plana for intravitreal injections. Graefes Arch Clin Exp Ophthalmol. 2021 Jun;259(6):1435-1441. doi: 10.1007/s00417-020-04967-3. Epub 2020 Oct 19.
PMID: 33074373DERIVEDWolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, Enzmann V, Framme C, Wolf S. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci. 2011 May 18;52(6):3334-7. doi: 10.1167/iovs.10-6097.
PMID: 21087958DERIVEDRothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol. 2009 May;147(5):831-7. doi: 10.1016/j.ajo.2008.12.005. Epub 2009 Feb 13.
PMID: 19217019DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sebastian Wolf, MD, PhD
University of Bern
- STUDY DIRECTOR
Sebastian Wolf, MD PhD
University of Bern
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
November 26, 2007
First Posted
November 27, 2007
Study Start
January 1, 2007
Primary Completion
November 27, 2023
Study Completion
November 28, 2023
Last Updated
November 29, 2023
Record last verified: 2023-11